Recently, of eight candidate biomarkers studied after adjustment for clinical predictors, apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and complement C1q subcomponent subunit B (C1QB) independently predicted rapid decline in eGFR in 345 people with type 2 diabetes. Here, APOA4 is linked to type 2 diabetes mellitus.